TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00788619

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfer of embryos on day 3 or day 5 after fertilization.
Description: Subjects will be allocated at random to the two arms. Group 1 will have two embryos transferred on day 3 based on nitric oxide concentration. Group 2 will have two embryos transferred on day 5 based on morphologic criteria.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Day 5 transfer
Description: Subjects will have embryo transfer on day 5 after fertilization. Selection of embryos to transfer will be based on morphologic criteria.
Study: NCT02076724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic mesh
Study: NCT03317730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xtampza ER
Description: Xtampza ER is a wax microsphere formulation of oxycodone that results in a nearly identical pharmacokinetic profile regardless of whether the capsule is intact when ingested or if ingested via enteral feeding tube as opposed to by mouth.
Study: NCT04050878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Facial scanner (Bellus3D) to assess perioral alterations
Description: Use of a digital caliper for conventional measurements and a facial scanner (Bellus3D) to analyse the modifications induced by the use of implant supported dental prostheses in the lip support
Study: NCT02499367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: nivolumab 3 mg/kg, every 2 weeks after induction treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: nivolumab 3 mg/kg, every 2 weeks after induction treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: nivolumab 3 mg/kg, every 2 weeks after induction treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: nivolumab 3 mg/kg, every 2 weeks after induction treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: nivolumab 3 mg/kg, every 2 weeks after induction treatment

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: 20 Gy to metastatic lesion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose doxorubicin
Description: 15 mg flat dose, once weekly for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: metronomic schedule, 50 mg daily orally for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 40 mg/m2, weekly for 2 weeks
Study: NCT02854956

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological, cognitive and behavioral assessment
Description: The assessment includes mainly :~* The Raven's Progressives matrices test which allow to assess the non-verbal reasoning mental age of the patient~* The Wechsler scale or Brunet Lézine scale which allow to assess The Intellectual Quotient~* The Peabody Picture Vocabulary Test Revised which allow to determine the Vocabulary age (receptive language).~* The Vineland adaptive behavioral scale which allow to assess the adaptive behavior~* The Nisonger child behavior rating form which allow to assess the behavior disorders~* Analogical visual reasoning task (eye-tracking assessment and behavior assessment) which allow to identify the strategy used to solve the task and provides an objective and quantitative assessment of visual analogical reasoning and cognitive inhibition.~* Kinematic analysis of a grasping movement which allow to study the effect of the orientation and the type of pinch on the movement duration and both the transport component and the grasp component.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological, cognitive and behavioral assessment
Description: The assessment includes mainly :~* The Raven's Progressives matrices test which allow to assess the non-verbal reasoning mental age of the patient~* The Wechsler scale or Brunet Lézine scale which allow to assess The Intellectual Quotient~* The Peabody Picture Vocabulary Test Revised which allow to determine the Vocabulary age (receptive language).~* The Vineland adaptive behavioral scale which allow to assess the adaptive behavior~* The Nisonger child behavior rating form which allow to assess the behavior disorders~* Analogical visual reasoning task (eye-tracking assessment and behavior assessment) which allow to identify the strategy used to solve the task and provides an objective and quantitative assessment of visual analogical reasoning and cognitive inhibition.~* Kinematic analysis of a grasping movement which allow to study the effect of the orientation and the type of pinch on the movement duration and both the transport component and the grasp component.
Study: NCT04398108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Margetuximab Margetuximab-IV
Description: Drug: Chosen Chemotherapy (Capecitabine) -Oral Capecitabine tablet Drug: Chosen Chemotherapy (Vinorelbine) Vinorelbine -IV Drug: Chosen Chemotherapy (Gemcitabine) Gemcitabine -IV
Study: NCT01135329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 IV daily on Day -6 through Day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 1 mg/kg PO OR 0.8 mg/kg IV four times daily on Day -6 through Day -3.
Study: NCT00036881

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc sulfate
Study: NCT00809809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zicam (Ionic zinc)
Description: 33mmol/l of ionic zinc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo swab
Study: NCT03504852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg
Description: sub-cutaneous secukinumab prefilled syringe 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: secukinumab 150 mg
Description: sub-cutaneous secukinumab prefilled syringe 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: secukinumab 150 mg
Description: sub-cutaneous secukinumab prefilled syringe 150 mg
Study: NCT00036881

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05189951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: circular motion
Description: The phlebotomy site was wiped in a circular motion from the center outwards, approximately 5x5 cm wide.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vertical motion
Description: The phlebotomy site was wiped vertically from top to bottom with a single maneuver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: circular+vertical motion
Description: The phlebotomy site was first vertically wiped from top to bottom with a single maneuver, and then it was wiped in a circular motion from the center to the outside.
Study: NCT05038384

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT00568048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10 mg/kg i.v., on day 1 of every cycle (14 days) until PD or any other event qualifying for stopping treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 150 mg/m2 p.o., on days 1-7 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
Study: NCT01963325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus Abraxane
Description: Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, \<1.25 m2: 80mg/day, 1.25\~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
Study: NCT04668196

Intervention type: DEVICE
Intervention: High-flow nasal cannula treatment
Description: Standard operating procedures represented by hihg-flow nasal cannula oxygen therapy

Intervention type: DEVICE
Intervention: Continuous positive airway pressure (CPAP) treatment
Description: Standard operating procedures represented by continuous positive airway pressure (CPAP) therapy

Intervention type: DEVICE
Intervention: Noninvasive ventilation treatment
Description: Standard operating procedures represented by noninvasive ventilation treatment
Study: NCT03918746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet Attachment-Based Compassion Therapy (iABCT)
Description: The internet version of Attachment-Based Compassion Therapy (iABCT) will be developed to be totally self-applied over the Internet through the website www.psicologiaytecnologia.com designed by Labpsitec (Laboratory of Psychology and Technology, Universitat Jaume I, and University of Valencia). The iABCT will consist of eight sequential modules: Module 0) Welcome module: approaching to the compassion; Module 1) Preparing ourselves for compassion. Kind attention; Module 2) Discovering our compassionate world; Module 3) Developing our compassionate world; Module 4) Understanding our relationship with compassion; Module 5) Working on ourselves; Module 6) Understanding the importance of forgiveness; Module 7) Consolidating the practice of compassion~The content will present through texts, audios, videos, pictures, vignettes, and interactive exercises. Downloadable PDF files will be available so that users can review them offline.
Study: NCT00466882

Intervention type: DEVICE
Intervention: Inamed Lap-Band System
Description: Patient's will be seen in the physician's office one week post surgery and once a month thereafter. The device can be gradually adjusted by the insertion of a needle into the port and saline is added or removed to inflate or deflate the LAPBAND. This can be conducted in the physician's office setting to enable the patient to lose 1-2 pounds per week over two years.
Study: NCT01405625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pictogram-based asthma action plan
Description: Asthma action plan using plain language, pictograms, and photographs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AAAAI standard of care written action plan
Study: NCT00572195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RNS® System
Description: The previously implanted RNS® System is programmed to provide responsive stimulation. Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. Patients with epilepsy treated with responsive direct-brain stimulation with the RNS System typically receive less than 6 minutes of stimulation a day.
Study: NCT02716389

Intervention type: OTHER
Group type: OTHER
Intervention: Zebris CMS 70

Intervention type: OTHER
Group type: OTHER
Intervention: Zebris CMS 70

Intervention type: OTHER
Group type: OTHER
Intervention: 3-D Bulls Eye Spirit Meter

Intervention type: OTHER
Group type: OTHER
Intervention: 3-D Bulls Eye Spirit Meter
Study: NCT01489943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 500 mg
Description: Subjects will receive 500 milligram (mg) (2 doses of 250 mg) GSK1605786 hard gelatin capsules twice daily orally on Days 5 to 14. GSK1605786 will be administered with 240 milliliter (mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg
Description: Subjects will receive 3 mg oral syrup of Midazolam once daily on Day 1 and Day 11. Midazolam will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg
Description: Subjects will receive 15 mg tablet of pioglitazone orally once daily on Day 2 and Day 12. Pioglitazone will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Description: Subjects will receive 40 mg hard gelatin capsules of Omeprazole once daily on Days 3 and 13. Omeprazole will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Description: Subjects will receive 10 mg tablet of Rosuvastatin orally once daily on Days 4 and 14. Rosuvastatin will be administered with 240 mL of water.
Study: NCT02026323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture
Study: NCT03424434

Intervention type: OTHER
Intervention: Survey diffusion
Description: The study consists in a survey diffusion during several weeks by emailing each practitioner and resident and inviting them to participate to a questionnaire about occupational blood exposure. This survey is strictly anonymous. No identity data is required, only age, gender, function, surgical or medical specialty, work quota and hospital group they belong. This survey is diffused in four UHC (Lyon, Grenoble, Clermont-Ferrand and Saint-Etienne) in France.
Study: NCT03977558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Isocaloric diet including \~50g canola oil

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: ESC/EAS Guidelines for the management of dyslipidemias
Study: NCT03089437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Standing
Description: Subject will stand for 12 hours and undergo a high fat tolerance test the subsequent day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Sitting
Description: Subject will sit for 12 hours and undergo a high fat tolerance test the subsequent day
Study: NCT02357251

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced recovery protocol
Study: NCT03846648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cypep-1
Description: Eligible subjects will be randomized to one of the two treatment groups in a ratio of 1:1 (active:placebo).~The treatment groups are:~* CyPep-1 topical formulation 1% (w/w)~* Vehicle topical formulation (placebo) The minimum set of studied warts is 1 treated common wart per subject. The subjects will be randomly assigned to treatment. During the treatment period topical formulation will be applied daily on to a maximum of 3 warts. One selected wart will serve as target wart, i.e. the primary wart, for detailed analysis. Selection of warts will be based on the feasibility to conduct treatment application and pharmacodynamics (including biopsy sampling) on the region of interest.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cypep-1
Description: Eligible subjects will be randomized to one of the two treatment groups in a ratio of 1:1 (active:placebo).~The treatment groups are:~* CyPep-1 topical formulation 1% (w/w)~* Vehicle topical formulation (placebo) The minimum set of studied warts is 1 treated common wart per subject. The subjects will be randomly assigned to treatment. During the treatment period topical formulation will be applied daily on to a maximum of 3 warts. One selected wart will serve as target wart, i.e. the primary wart, for detailed analysis. Selection of warts will be based on the feasibility to conduct treatment application and pharmacodynamics (including biopsy sampling) on the region of interest.
Study: NCT03289234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: 30 mg of edaravone will be administered intravenously over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: 30 mg of edaravone will be administered intravenously over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: 30 mg of edaravone will be administered intravenously over 60 minutes
Study: NCT00939445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Online HDF
Description: Online HDF

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short Daily Hemodialysis
Description: Short Daily Hemodialysis
Study: NCT02669264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-402
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-402
Description: Intravenous infusion
Study: NCT01562795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonsteroid anti-inflammatory drops
Description: nonsteroid anti-inflammatory drops plus artificial tear substitute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonsteroid anti-inflammatory drops
Description: nonsteroid anti-inflammatory drops plus artificial tear substitute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: corticosteroids plus artificial tear substitute

Intervention type: DRUG
Group type: OTHER
Intervention: artificial tear substitute
Description: artificial tear substitute alone
Study: NCT00969332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: 0.5 g/kg/d intravenous every day for 2 days, then 1 g/kg/d intravenous everyday
Study: NCT02226796

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation tool that presents a low current that induces bi-directional polarity-dependent changes in the cortex to facilitate focal, prolonged shifts in cortical excitability at or around the time stimulation is provided. Anodal tDCS (a-tDCS), in which the positively charged electrode is placed over the targeted cortical region, has been shown to increase cortical excitability (upregulation), similar to long-term potentiation (LTP). Combining a-tDCS with behavioral-based approaches has been suggested to enhance the learning process and increase the likelihood of retention.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation tool that presents a low current that induces bi-directional polarity-dependent changes in the cortex to facilitate focal, prolonged shifts in cortical excitability at or around the time stimulation is provided. Anodal tDCS (a-tDCS), in which the positively charged electrode is placed over the targeted cortical region, has been shown to increase cortical excitability (upregulation), similar to long-term potentiation (LTP). Combining a-tDCS with behavioral-based approaches has been suggested to enhance the learning process and increase the likelihood of retention.
Study: NCT00818714

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT x 3 (start 6-9 weeks following standard ChemoRT; Time between SBRT Boost treatments: 40 hours to 8 days)~Dose Escalation Schema:~Cohort -3: 4 Gy x3 Cohort -2: 5 Gy x3 Cohort -1: 6 Gy x3 If de-escalation is required after initial cohort~Cohort 1: 7 Gy x 3 INITIAL COHORT Cohort 2: 8 Gy x 3 Cohort 3: 9 Gy x 3~Continue +1 Gy x 3 until reach MTD
Study: NCT00654485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study: NCT00815867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin beta (NeoRecormon ®)
Description: comparison of administration of high dosage of epoetin vs no administration of epoetin~30000 UI: 4 injections
Study: NCT02651766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cupping massage
Description: Using suction on the skin by means of glass cups, and moving the cups after applying massage oil on the skin
Study: NCT03570398

Intervention type: OTHER
Group type: OTHER
Intervention: unenhanced abdomino-pelvic CT scan
Description: unenhanced abdomino-pelvic CT scan

Intervention type: OTHER
Group type: OTHER
Intervention: abdominal ultrasound
Description: abdominal ultrasound
Study: NCT05100290

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperventilation Provocation Test (HPTest)
Description: During the HPTest, the subject is comfortably seated in a chair with armrests and breathes in a mouthpiece with a salivary collector and a nasal clamp. Parameters of ventilation and gas exchange are analyzed via an Oxycon ProTM (SN808008) with TripleV-Volume Sensor digital(Jaeger).~The HPTest begins with a 3-minutes adaptation phase during which the patient is asked to breathe normally. During the 3-minutes of voluntary hyperventilation phase, the patient is asked to increase his tidal volume and support a breath rate of at least 30/min in order to reduce his PETCO2 by at least 50%. During the recovery phase of the HPTest, the patient is invited to regain a natural breathing for 5 minutes, without guidance on tidal volume or breath rate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperventilation Provocation Test (HPTest)
Description: During the HPTest, the subject is comfortably seated in a chair with armrests and breathes in a mouthpiece with a salivary collector and a nasal clamp. Parameters of ventilation and gas exchange are analyzed via an Oxycon ProTM (SN808008) with TripleV-Volume Sensor digital(Jaeger).~The HPTest begins with a 3-minutes adaptation phase during which the patient is asked to breathe normally. During the 3-minutes of voluntary hyperventilation phase, the patient is asked to increase his tidal volume and support a breath rate of at least 30/min in order to reduce his PETCO2 by at least 50%. During the recovery phase of the HPTest, the patient is invited to regain a natural breathing for 5 minutes, without guidance on tidal volume or breath rate.
Study: NCT01135329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg IV daily on Day +3 and Day +4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg PO three times daily (max daily dose of 3g) starting on Day +5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Dosed based on drug levels; begin on Day +5 at 1 mg IV daily.
Study: NCT02270047

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Orange nectar
Description: Orange nectar

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange Nectar with fibre
Study: NCT04411394

Intervention type: OTHER
Intervention: Questionnaire
Description: Body Perception Questionnaire and Hospitalized Anxiety and Depression Scale

Intervention type: OTHER
Intervention: Questionnaire
Description: Body Perception Questionnaire and Hospitalized Anxiety and Depression Scale
Study: NCT02464813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Patients will receive pregabalin twice preoperatively and twice daily for 5 days after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Patients will receive placebo twice preoperatively and twice daily for 5 days after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: All patients will receive oxycodone as analgetic treatment administered by PCA. Oxycodone consumption will be measured.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: All patients will receive oxycodone as analgetic treatment administered by PCA. Oxycodone consumption will be measured.